1/19/2026

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Pevisone

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Ekonazol

Ekonazol

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Martindale. Clotrimazole. Micromedex [www]. [cited 2022-12-02].

  2. Trimb Healthcare AB. Produktresumé Pevaryl. Läkemedelsverket [www]. [cited 2022-12-02].

  3. Rosa FW, Baum C, Shaw M. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet Gynecol. 1987;69:751-5.

  4. Tan CG, Good CS, Milne LJ, Loudon JD. A comparative trial of six day therapy with clotrimazole and nystatin in pregnant patients with vaginal candidiasis. Postgrad Med J. 1974;50 Suppl 1(0):102-5.

  5. Frerich W, Gad A. The frequency of Candida infections in pregnancy and their treatment with clotrimazole. Curr Med Res Opin. 1977;4(9):640-4.

  6. Haram K, Digranes A. Vulvovaginal candidiasis in pregnancy treated with clotrimazole. Acta Obstet Gynecol Scand. 1978;57(5):453-5.

  7. Patel VM, Schwartz RA, Lambert WC. Topical antiviral and antifungal medications in pregnancy: a review of safety profiles. J Eur Acad Dermatol Venereol. 2017;31(9):1440-1446.

  8. Rotem R, Fishman B, Daniel S, Koren G, Lunenfeld E, Levy A. Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. BJOG. 2018;125(12):1550-1556.

  9. Czeizel AE, Rockenbauer M. A lower rate of preterm birth after clotrimazole therapy during pregnancy. Paediatr Perinat Epidemiol. 1999;13:58-64.

  10. Daniel S, Rotem R, Koren G, Lunenfeld E, Levy A. Vaginal antimycotics and the risk for spontaneous abortions. Am J Obstet Gynecol. 2018;218(6):601e1-601e7.

  11. Czeizel AE, Toth M, Rockenbauer M. No teratogenic effect after clotrimazole therapy during pregnancy. Epidemiology 1999;10:437-40.

  12. Czeizel AE, Fladung B, Vargha P. Preterm birth reduction after clotrimazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2004;116(2):157-63.

  13. Bánhidy F, Acs N, Puho EH, Czeizel AE. Rate of preterm births in pregnant women with common lower genital tract infection: a population-based study based on the clinical practice. J Matern Fetal Neonatal Med. 2009;22(5):410-8.

  14. Roberts CL, Rickard K, Kotsiou G, Morris JM. Treatment of asymptomatic vaginal candidiasis in pregnancy to prevent preterm birth: an open-label pilot randomized controlled trial. BMC Pregnancy Childbirth. 2011;11(11):18.

  15. Genovese C, Corsello S, Nicolosi D, Aidala V, Falcidia E, Tempera G. Alterations of the vaginal microbiota in the third trimester of pregnancy and pPROM. Eur Rev Med Pharmacol Sci. 2016;20(16):3336-43.

  16. Farr A, Kiss H, Holzer I, Husslein P, Hagmann M, Petricevic L. Effect of asymptomatic vaginal colonization with Candida albicans on pregnancy outcome. Acta Obstet Gynecol Scand. 2015;94(9):989-96.

  1. Martindale. Clotrimazole. Micromedex [www]. [cited 2022-12-02].
  2. Trimb Healthcare AB. Produktresumé Pevaryl. Läkemedelsverket [www]. [cited 2022-12-02].
  3. Rosa FW, Baum C, Shaw M. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet Gynecol. 1987;69:751-5.
  4. Tan CG, Good CS, Milne LJ, Loudon JD. A comparative trial of six day therapy with clotrimazole and nystatin in pregnant patients with vaginal candidiasis. Postgrad Med J. 1974;50 Suppl 1(0):102-5.
  5. Frerich W, Gad A. The frequency of Candida infections in pregnancy and their treatment with clotrimazole. Curr Med Res Opin. 1977;4(9):640-4.
  6. Haram K, Digranes A. Vulvovaginal candidiasis in pregnancy treated with clotrimazole. Acta Obstet Gynecol Scand. 1978;57(5):453-5.
  7. Patel VM, Schwartz RA, Lambert WC. Topical antiviral and antifungal medications in pregnancy: a review of safety profiles. J Eur Acad Dermatol Venereol. 2017;31(9):1440-1446.
  8. Rotem R, Fishman B, Daniel S, Koren G, Lunenfeld E, Levy A. Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. BJOG. 2018;125(12):1550-1556.
  9. Czeizel AE, Rockenbauer M. A lower rate of preterm birth after clotrimazole therapy during pregnancy. Paediatr Perinat Epidemiol. 1999;13:58-64.
  10. Daniel S, Rotem R, Koren G, Lunenfeld E, Levy A. Vaginal antimycotics and the risk for spontaneous abortions. Am J Obstet Gynecol. 2018;218(6):601e1-601e7.
  11. Czeizel AE, Toth M, Rockenbauer M. No teratogenic effect after clotrimazole therapy during pregnancy. Epidemiology 1999;10:437-40.
  12. Czeizel AE, Fladung B, Vargha P. Preterm birth reduction after clotrimazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2004;116(2):157-63.
  13. Bánhidy F, Acs N, Puho EH, Czeizel AE. Rate of preterm births in pregnant women with common lower genital tract infection: a population-based study based on the clinical practice. J Matern Fetal Neonatal Med. 2009;22(5):410-8.
  14. Roberts CL, Rickard K, Kotsiou G, Morris JM. Treatment of asymptomatic vaginal candidiasis in pregnancy to prevent preterm birth: an open-label pilot randomized controlled trial. BMC Pregnancy Childbirth. 2011;11(11):18.
  15. Genovese C, Corsello S, Nicolosi D, Aidala V, Falcidia E, Tempera G. Alterations of the vaginal microbiota in the third trimester of pregnancy and pPROM. Eur Rev Med Pharmacol Sci. 2016;20(16):3336-43.
  16. Farr A, Kiss H, Holzer I, Husslein P, Hagmann M, Petricevic L. Effect of asymptomatic vaginal colonization with Candida albicans on pregnancy outcome. Acta Obstet Gynecol Scand. 2015;94(9):989-96.
2 2
2 2

Triamcinolon – för hud och slemhinnor

Triamcinolon – för hud och slemhinnor

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol. 2014;59(5):460-4.

  2. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015;10:CD007346.

  3. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol. 2007;197(6):585e1-7; discussion 683-4, e1-7.

  4. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796-804.

  5. Edwards MJ, Agho K, Attia J, Diaz P, Hayes T, Illingworth A et al. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am J Med Genet 2003;120A:459-63.

  6. Mygind H, Thulstrup AM, Pedersen L, Larsen H. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta Obstet Gynecol Scand 2002;81:234-9.

  7. Skuladottir H, Wilcox AJ, Ma C, Lammer EJ, Rasmussen SA, Werler MM et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol. 2014;100(6):499-506.

  8. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997;56:335-40.

  9. APL. Triamcinolon APL 0,1 % Munhålegel Produktmonografi. AIDA APL [www]. [updated 2016-03-15, cited 2025-12-16].

  10. Läkemedelsverket. Pevisone Produktresumé. Läkemedelsverket [www]. [updated 2023-05-26, cited 2025-12-16].

  11. Ramadas AA, Jose R, Arathy SL, Kurup S, Chandy ML, Kumar SP. Systemic absorption of 01% triamcinolone acetonide as topical application in management of oral lichen planus. Indian J Dent Res. 2016;27(3):230-5.

  12. Katz VL, Thorp JM, Bowes WA. Severe symmetric intrauterine growth retardation associated with the topical use of triamcinolone. Am J Obstet Gynecol. 1990;162(2):396-7.

  1. Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol. 2014;59(5):460-4.
  2. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015;10:CD007346.
  3. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol. 2007;197(6):585e1-7; discussion 683-4, e1-7.
  4. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796-804.
  5. Edwards MJ, Agho K, Attia J, Diaz P, Hayes T, Illingworth A et al. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am J Med Genet 2003;120A:459-63.
  6. Mygind H, Thulstrup AM, Pedersen L, Larsen H. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta Obstet Gynecol Scand 2002;81:234-9.
  7. Skuladottir H, Wilcox AJ, Ma C, Lammer EJ, Rasmussen SA, Werler MM et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol. 2014;100(6):499-506.
  8. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997;56:335-40.
  9. APL. Triamcinolon APL 0,1 % Munhålegel Produktmonografi. AIDA APL [www]. [updated 2016-03-15, cited 2025-12-16].
  10. Läkemedelsverket. Pevisone Produktresumé. Läkemedelsverket [www]. [updated 2023-05-26, cited 2025-12-16].
  11. Ramadas AA, Jose R, Arathy SL, Kurup S, Chandy ML, Kumar SP. Systemic absorption of 01% triamcinolone acetonide as topical application in management of oral lichen planus. Indian J Dent Res. 2016;27(3):230-5.
  12. Katz VL, Thorp JM, Bowes WA. Severe symmetric intrauterine growth retardation associated with the topical use of triamcinolone. Am J Obstet Gynecol. 1990;162(2):396-7.